International Journal of Rheumatic Diseases最新文献

{"title":"Case Report: Can Chronic Relapsing Multifocal Osteomyelitis (CRMO) Be Combined With Hematologic Neoplasms?","authors":"Junhan Wen, Fanzhang Meng, Naigang Chen, Han Sheng, Xiujuan Hou, Chen Li","doi":"10.1111/1756-185X.70294","DOIUrl":"https://doi.org/10.1111/1756-185X.70294","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-Occurrence of Hemophilia and Ankylosing Spondylitis in a Pair of Identical Twins","authors":"Yan Lin Zhang, Chun Cao, Yun Luo","doi":"10.1111/1756-185X.70277","DOIUrl":"https://doi.org/10.1111/1756-185X.70277","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Dietary Index for Gut Microbiota With Hyperuricemia in Adults: A Cross-Sectional Study of NHANES 2007–2018","authors":"Fengjiao Cao,&nbsp;Siyi Lu,&nbsp;Wenming Yi,&nbsp;Mengwei Wu,&nbsp;Junhan Wen,&nbsp;Zhengze Dai,&nbsp;Xiujuan Hou","doi":"10.1111/1756-185X.70289","DOIUrl":"https://doi.org/10.1111/1756-185X.70289","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To detect the potential association between the dietary index for gut microbiota (DI-GM) and hyperuricemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Utilizing cross-sectional analysis of National Health and Nutrition Examination Survey (NHANES) data, a multivariable logistic regression model was employed to reveal the impact of DI-GM on uric acid levels. The results indicate that participants with hyperuricemia had significantly lower DI-GM levels compared to those without hyperuricemia (OR = 0.93, 95% CI: 0.91–0.95, <i>p</i> &lt; 0.001). Furthermore, even after adjusting for covariates, the association between DI-GM and hyperuricemia remained significant (OR = 0.97, 95% CI: 0.95–0.99, <i>p</i> = 0.012), suggesting a risk factor association between high DI-GM and low uric acid levels. The study also revealed a gradual decrease in the risk of hyperuricemia with increasing DI-GM, indicating the potential of DI-GM as a prognostic assessment marker (<i>p</i> for overall &lt; 0.001). Additionally, a weak negative correlation between DI-GM and chronic kidney disease (CKD) was observed among patients with hyperuricemia (Adjusted OR = 0.90, 95% CI: 0.82–0.99, <i>p</i> = 0.027).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings support the utility of DI-GM as a potential biomarker with important implications for the prevention and treatment of hyperuricemia. This discovery provides a crucial basis for the development of future dietary interventions and strategies related to gut microbiota, warranting further in-depth research to validate its applicability and effectiveness in diverse populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baricitinib as a Steroid Sparing Agent to Curb the Immune Dysregulation Associated With Heterozygous STAT3 Mutations Causing Gain-Of-Function: A Case Report","authors":"Akshaya Chougule,&nbsp;Vijaya Gowri,&nbsp;Vaishnavi Iyengar,&nbsp;Prasad Taur,&nbsp;Manisha Madkaikar,&nbsp;Minnie Bodhanwala,&nbsp;Mukesh M. Desai","doi":"10.1111/1756-185X.70291","DOIUrl":"https://doi.org/10.1111/1756-185X.70291","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Case Report: Nutcracker Syndrome Triggered by Rapid Weight Loss in a Patient With Systemic Lupus Erythematosus”","authors":"","doi":"10.1111/1756-185X.70287","DOIUrl":"https://doi.org/10.1111/1756-185X.70287","url":null,"abstract":"<p>Li, C., Wang, Y.-w., Sheng, H., Jin, D., Shu, Z.-x., Li, M. and Li, S.-G. (2025), Case Report: Nutcracker Syndrome Triggered by Rapid Weight Loss in a Patient With Systemic Lupus Erythematosus. <i>Int J Rheum Dis</i>, 28: e70190. https://doi.org/10.1111/1756-185X.70190</p><p>In the above article, the second affiliation of the author, Chen Li, and the order of the two authors listed in the correspondence section were incorrect.</p><p>The first affiliation of the author, Chen Li, should be as follows: “Department of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.”</p><p>The order of authors in the correspondence section should first be “Sheng-Guang Li”, then “Ming Li”.</p><p>The online article has been corrected.</p><p>We apologize for the errors.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70287","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Industry Payments to US Editorial Board Members of Major Rheumatology Journals","authors":"Netanja I. Harlianto","doi":"10.1111/1756-185X.70280","DOIUrl":"https://doi.org/10.1111/1756-185X.70280","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential Role of CAR T Cell Therapy in Autoimmune Diseases","authors":"Jie-Fu Zheng,&nbsp;Yeak-Wun Quek,&nbsp;James Cheng-Chung Wei","doi":"10.1111/1756-185X.70192","DOIUrl":"https://doi.org/10.1111/1756-185X.70192","url":null,"abstract":"&lt;p&gt;Adaptive immunity, constituted by T cells and B cells, forms an integral part of the immune system. Characterized by its ability to learn and remember, adaptive immunity aims to prompt a faster immune response upon reencounter with similar threats. This learning can stem from vaccination or infections, albeit the latter typically come with higher health risks. Among these adaptive immune cells, B cells primarily produce antibodies and assist T cells, which exist in various types. Some T cells (Th1, Th17) promote inflammatory responses, others (Th2) aid B cells in antibody production, and a few (Tc, NKT) can directly eliminate virus-infected or cancerous cells. Treg cells, however, act as immune brakes to prevent excessive immune activation. T cells express unique receptors (T cell receptors) on their surfaces during development, which, upon binding with antigens from foreign pathogens or aberrant cells, activate the T cells' functions. The thymus plays a crucial role in T cell development by eliminating unfit T cells. Unfit T cells, such as those that strongly bind to normal bodily cells, undergo apoptosis within the thymus to prevent attacking healthy cells. Consequently, thymectomy, as seen in conditions like myasthenia gravis, may increase the risk of autoimmune diseases like systemic lupus erythematosus [&lt;span&gt;1&lt;/span&gt;]. B cell quality control primarily occurs in the bone marrow, where potentially self-attacking autoantibody-producing B cells are either reprogrammed or led to apoptosis.&lt;/p&gt;&lt;p&gt;With this understanding, the recent buzz around “CAR T” cell therapy becomes clearer. “T” in CAR T stands for T cells, while “CAR” is an acronym for chimeric antigen receptor. In essence, CAR T therapy involves using retroviruses to insert designed genes into T cells, allowing them to express receptors that bind to cancer cells, thus enabling them to attack the cancer. CAR T cell therapy has shown notable success in treating lymphoma. Early experiments, such as those by Brentjens and colleagues at the Memorial Sloan-Kettering Cancer Center in 2003, demonstrated effective lymphoma cell elimination in mice with genetically modified T cells expressing CD19-binding receptors [&lt;span&gt;2&lt;/span&gt;]. CD19, a glycoprotein on B cell surfaces, does not normally trigger T cell responses owing to negative selection during T cell development. In 2010, Kochenderfer and other researchers at the National Cancer Institute successfully reduced tumors in a patient with B cell lymphoma using CD19-targeted CAR T therapy. Studies indicate that CAR T therapy targeting CD19 can completely eliminate tumors in approximately 40%–54% of cases involving aggressive, treatment-resistant B cell lymphoma [&lt;span&gt;3&lt;/span&gt;]. Long-term studies, like those by Cappell and colleagues from the National Institutes of Health, report a 51% non-recurrence rate over 3 years in B cell lymphoma treatments [&lt;span&gt;4&lt;/span&gt;]. For relapsed or refractory B cell acute lymphoblastic leukemia in children, CD19-","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70192","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of the Early Combination of Anti-Inflammation With Urate-Lowering Therapy in Acute Gout","authors":"Jiasheng Ma,&nbsp;Fengju Li,&nbsp;Yong Du,&nbsp;An-Ping Huo,&nbsp;Xuewu Zhang","doi":"10.1111/1756-185X.70302","DOIUrl":"https://doi.org/10.1111/1756-185X.70302","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib Versus Methotrexate in Treating Mucocutaneous and Musculoskeletal Lesions of Systemic Lupus Erythematosus: Real-World Results From the CSTAR Cohort XXXII","authors":"Man Zhao,&nbsp;Leyao Ma,&nbsp;Xinwang Duan,&nbsp;Yuehong Huo,&nbsp;Shengyun Liu,&nbsp;Cheng Zhao,&nbsp;Qian Wang,&nbsp;Xinping Tian,&nbsp;Yunzhuan Chen,&nbsp;Mengtao Li","doi":"10.1111/1756-185X.70283","DOIUrl":"https://doi.org/10.1111/1756-185X.70283","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to evaluate and compare the efficacy and safety of tofacitinib versus methotrexate in the management of systemic lupus erythematosus (SLE) within a real-world cohort, with a particular focus on mucocutaneous and musculoskeletal involvement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective analysis based on the Chinese SLE Treatment and Research Group (CSTAR) cohort. Patients with SLE presenting with active mucocutaneous or musculoskeletal involvement who initiated treatment with tofacitinib or methotrexate were included. The primary endpoint was the proportion of patients achieving resolution of mucocutaneous and musculoskeletal symptoms, as defined by the SLE Disease Activity Index 2000, at 3 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 109 patients were included in the study, with 44 assigned to the tofacitinib group and 65 to the methotrexate group. The tofacitinib group exhibited a numerically higher trend in resolution proportion for both mucocutaneous (3 months: 88.0% vs. 69.6%, <i>p</i> = 0.162; 6 months: 83.3% vs. 77.8%, <i>p</i> &gt; 0.999) and musculoskeletal (100.0% vs. 84.6%, <i>p</i> = 0.555; 100.0% vs. 73.7%, <i>p</i> = 0.289) involvement compared with the methotrexate group. However, these differences did not reach statistical significance. Survival analysis revealed that tofacitinib was associated with a faster resolution of mucocutaneous (<i>p</i> = 0.043) involvement compared to methotrexate within a 6-month follow-up period. There was no significant difference in the incidence of adverse events between the two groups (2.3% vs. 3.1%, <i>p</i> &gt; 0.999).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Tofacitinib may demonstrate superior effectiveness over methotrexate in the resolution of mucocutaneous involvement in SLE patients, primarily by achieving remission more rapidly, while maintaining a comparable safety profile.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Extracorporeal Membrane Oxygenation for the Treatment of Diffuse Alveolar Hemorrhage in Granulomatosis With Polyangiitis: A Case Report","authors":"Atif S Siddiqui,&nbsp;Sarah A Kazzaz","doi":"10.1111/1756-185X.70298","DOIUrl":"https://doi.org/10.1111/1756-185X.70298","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144108847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}